Innovent will push VANFLYTA deeper into China’s AML market as Daiichi Sankyo supplies the drug.
This is a meaningful China oncology commercialization move for both companies and a direct access story for a high-risk AML population.
AI reasoning
This is a meaningful China oncology commercialization move for both companies and a direct access story for a high-risk AML population.
Curated summary
Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement for VANFLYTA commercialization in Mainland China. Daiichi Sankyo will handle development, manufacturing and supply, while Innovent gets sole commercialization rights and market promotion. VANFLYTA, or quizartinib, was approved in China in June 2026 for newly diagnosed FLT3-ITD-positive acute myeloid leukemia.
Supporting evidence
YouTube·CNBC International LiveDaiichi Sankyo shares growth projections, says its oncology business is a 'growth driver'
611 engagements6h ago
YouTube·CNBC International LiveApproaching the business with a 'patient-centric mindset': Daiichi Sankyo CEO
490 engagements6h ago
YouTube·Vinod Kothari & CompanyDraft Foreign Investment Rules: A proposal to replace NDI Rules
276 engagements6h ago
YouTube·INOVIQINOVIQ | EXO-OC Study Outcome Investor Webinar (14 July 2026)
96 engagements6h ago
YouTube·ConCall IndiaTenneco Clean Air India Ltd Q1 FY2026-27 Concall
30 engagements6h ago
YouTube·Murthy Finance AcademyBeyond IT Services: Is Indegene the Ultimate "Strategic Operating Partner" for Global Pharma? 🧬💻
16 engagements6h ago
YouTube·Corporate DecoderCYCN's Massive Merger & Dilution: My Take on the S-4 Filing
8 engagements6h ago
YouTube·Bloomberg TelevisionInnovent Biologics CEO on Pharma Industry, Prices, Pipeline, Cancer Cure
6h ago
Source news
Innovent and Daiichi Sankyo strike China deal for VANFLYTA commercialization
The partners have signed an exclusive agreement for quizartinib in Mainland China, where the drug was approved in June for FLT3-ITD-positive AML.
